Quality and predictors of anticoagulant control with vitamin K antagonist for stroke prevention in atrial fibrillation

Thrombosis and Haemostasis

Volumn 116, Issue 3, 2016, Pages 578-580

  Wilson, Matthew R ^a   Parakramawansha, Ruwan ^a   Quinn, Terence J ^b   Tait, Robert C ^a,b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; CORTICOSTEROID; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DRUG DOSE TITRATION; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEOPLASM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SOCIAL STATUS; THERAPY EFFECT; TIME IN THERAPEUTIC RANGE; ANTAGONISTS AND INHIBITORS; COMPLICATION; MIDDLE AGED; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE; TIME FACTORS; VITAMIN K; WARFARIN;

EID: 84989201946     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-01-0025     Document Type: Letter

References (9)

1. White HD, Gruber M, Feyzi J, et al.Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.Arch Intern Med 2007; 167: 239-245.
2. National Institute for Health and Clinical Excellence (NICE).Atrial fibrillation: the management of atrial fibrillation.NICE clinical guideline 180. Issued June 2014; 1-5-2015.
3. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
4. Costa GL, Lamego RM, Colosimo EA, et al. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin Ther 2012; 34: 1511-1520.
5. Apostolakis S, Sullivan RM, Olshansky B, et al.Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 2013; 144: 1555-1563.
6. Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010; 8: 2182-2191.
7. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
8. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144: 1555-1563.
9. Abdul-Rahim AH, Wong J, McAlpine C, et al. Associations with anticoagulation: a cross-sectional registry-based analysis of stroke survivors with atrial fibrillation. Heart 2014; 100: 557-562.